Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

Presentation TCT 2017

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? Yes, Based on TROPICAL-ACS, TRITON, and Other Studies!

Presenter: John A. Bittl, Freek W.A. Verheugt, Dirk Sibbing

October 30, 2017

Presentation TCT 2017

Should Choice of Parenteral Therapy for Primary PCI in STEMI Depend on Vascular Access?

Presenter: Michael S. Lee, Dirk Sibbing, John A. Bittl

October 30, 2017

Presentation TCT 2017

Parenteral Therapy in STEMI: Does VALIDATE Change the Equation?

Presenter: Michael S. Lee, Dirk Sibbing, David Erlinge

October 30, 2017

Presentation TCT 2017

Why I Use Cangrelor for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Dmitriy N. Feldman

October 30, 2017

Presentation TCT 2017

Why I Prefer Bivalirudin for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Uwe Zeymer

October 30, 2017

Presentation TCT 2017

Why I Prefer a Heparin Plus a GPI for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Eric R. Bates

October 30, 2017

$Why I Prefer Unfractionated Heparin Without GPI for Primary PCI in STEMI!$

Presentation TCT 2017

Why I Prefer Unfractionated Heparin Without GPI for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, A. Michael Lincoff

October 30, 2017

Presentation TCT 2017

STEMI Case Presentation: Why the Choice of Patental Therapy Matters

Presenter: Michael S. Lee, Dirk Sibbing, Francesco Franchi

October 30, 2017

Presentation TCT 2014

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

Presenter: Dirk Sibbing

September 14, 2014

Presentation TCT 2014

De-escalating Antiplatelet Treatment in ACS Patients: New Concepts and Upcoming Studies

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Dirk Sibbing

September 14, 2014

News Conference News TCT 2012

Presentations Examine Multiple Facets of Antiplatelet Agents

October 24, 2012

Presentation TCT 2012

P2Y12 Inhibitors: Specific Agents for Specific Patient Cohorts? (STEMI, Diabetes, CKD, Prior Stroke, Etc.)

Presenter: Dirk Sibbing

October 22, 2012

News Conference News

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

November 09, 2011

Advertisement

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? Yes, Based on TROPICAL-ACS, TRITON, and Other Studies!

Should Choice of Parenteral Therapy for Primary PCI in STEMI Depend on Vascular Access?

Parenteral Therapy in STEMI: Does VALIDATE Change the Equation?

Why I Use Cangrelor for Primary PCI in STEMI!

Why I Prefer Bivalirudin for Primary PCI in STEMI!

Why I Prefer a Heparin Plus a GPI for Primary PCI in STEMI!

Why I Prefer Unfractionated Heparin Without GPI for Primary PCI in STEMI!

STEMI Case Presentation: Why the Choice of Patental Therapy Matters

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

De-escalating Antiplatelet Treatment in ACS Patients: New Concepts and Upcoming Studies

Presentations Examine Multiple Facets of Antiplatelet Agents

P2Y12 Inhibitors: Specific Agents for Specific Patient Cohorts? (STEMI, Diabetes, CKD, Prior Stroke, Etc.)

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content